Nasdaq Initiates Delisting Process for Dyadic International After Missed Compliance Deadline
DYAI sits 30% above its 52-week low of $0.655.
Summary
Nasdaq has initiated a delisting process for Dyadic International after the company failed to meet the minimum bid price requirement and did not qualify for an extension.
Key Events · Corporate Governance and Compliance · DYAI
-
Nasdaq Initiates Delisting Process
On June 18, 2026, Nasdaq notified Dyadic International that it has initiated a process that could result in the delisting of the company's securities.
-
Failed Bid Price Compliance
The company failed to regain compliance with Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share, by the June 17, 2026 deadline.
-
Did Not Qualify for Extension
Dyadic International did not meet the condition for an additional 180-day extension, which required shareholders' equity of at least $5 million.
-
Additional Delisting Basis Cited
Nasdaq also cited the company's failure to comply with Listing Rule 5550(b), requiring minimum shareholders' equity of $2.5 million, market value of $35 million, or $500,000 net income.
Analysis · DYAI · Life Sciences
Nasdaq has formally initiated delisting proceedings against Dyadic International because the company failed to regain compliance with the $1.00 minimum bid price rule by the June 17, 2026 deadline. Crucially, the company also did not meet the $5 million shareholders' equity requirement to qualify for an extension, intensifying the risk of delisting. This development significantly impacts the company's ability to maintain its public listing, which is critical for liquidity and future capital raising efforts, especially given its negative shareholder equity reported in Q1 2026.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 39.1% of the 317 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DYAI was trading at $0.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.9M. The 52-week trading range was $0.65 to $1.35. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.